Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio
13 janv. 2025 19h04 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”)...
Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
20 déc. 2024 03h30 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Chris Cargill,...
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia
18 déc. 2024 21h35 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd....
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea
04 déc. 2024 19h05 HE
|
Nxera Pharma
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ™ (daridorexant) 25 and 50 mg was recently approved and is expected...
Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist
12 nov. 2024 19h01 HE
|
Nxera Pharma
Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd....
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
05 nov. 2024 02h00 HE
|
Nxera Pharma
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies...
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024
01 nov. 2024 02h30 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational...
Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024
23 oct. 2024 03h00 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won...
Nxera Pharma to Host R&D Day 2024
18 oct. 2024 05h38 HE
|
Nxera Pharma
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date:...
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
01 oct. 2024 02h04 HE
|
Nxera Pharma
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of...